|
While researching neuroscience companies, I came across CoCensys(COCN)...There were no posts on the board, but I found H&Q referring to it as a "hidden gem"...From what I've read, the company has the following to recommend it: (a) 3 Phase 11 trials in adult epilepsy, pediatric epilepsy, and migraines (b) a Phase 1 trial in traumatic brain injury- with some data apparently to be disclosed at Am.HeartAssn. mtg.in Feb. (c) preparation for filing for Phase 1 trials in insomnia in '97 (d) Ciba and Searle as partners and (e) a 60 person sales force selling marketed drugs...There are some 22 million shares out...With a Friday close of $6. the cap. is about $130 million...Subtract the 30 million+ in cash and you value the "technology" at <$100 million...I had originally set out to make a case for purchasing Neurogen...However, the research regarding COCN appears to argue that it may offer better opportunity...I would appreciate any input/argument/support/dissension.......... |
